echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Zai Lab's ROS1/NTRK targeted inhibitor included in breakthrough therapy

    Zai Lab's ROS1/NTRK targeted inhibitor included in breakthrough therapy

    • Last Update: 2022-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 17, Zai Lab announced that the next-generation tyrosine kinase inhibitor (TKI) repotrectinib has been included in the breakthrough therapy category in China for patients with ROS1-positive metastatic non-small cell lung cancer who have not received ROS1 TKI therapy


    According to public information, repotrectinib is a ROS1 and NTRK targeted inhibitor developed by Turning Point


    Tumors with mutations in the ROS1 and NTRK genes are more likely to develop resistance to existing targeted therapies


    It is reported that the inclusion of repotrectinib as a breakthrough therapy in China is based on preliminary data from global and Chinese TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC) patients who participated in 1/2 of TRIDENT-1 period research


    According to the public information of Zai Lab, in May 2021, the TRIDENT-1 study completed the first patient dosing in China


    In October 2021, repotrectinib was granted breakthrough therapy designation by the FDA for the treatment of patients with advanced solid tumors harboring NTRK gene fusions


    references:

    [1] Zai Lab Announces Breakthrough Therapy Designation for Repotrectinib in China.


    [2] Zai Lab Announces Repotrectinib Phase 2 Registration Study TRIDENT-1 Completed the First Patient Dosing in China.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.